GlycoMimetics (GLYC) Stock Price, News & Analysis

Company Overview

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.16 to $27.47
• 52-Week Range: N/A
• Volume: 1.05 million shs
• Average Volume: 67,672 shs
• Market Capitalization: $10.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

GlycoMimetics Stock Analysis - MarketRank™

GlycoMimetics scored higher than 10% of companies evaluated by MarketBeat, and ranked 891st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for GlycoMimetics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for GlycoMimetics are expected to remain at ($0.08) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GlycoMimetics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GLYC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GlycoMimetics does not currently pay a dividend.

Dividend Growth

GlycoMimetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.55

Short Interest

There is no current short interest data available for GLYC.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for GlycoMimetics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GlycoMimetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.70% of the stock of GlycoMimetics is held by insiders.

Percentage Held by Institutions

75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLYC Stock Analysis - Frequently Asked Questions

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) issued its quarterly earnings data on Wednesday, May, 14th. The biotechnology company reported ($4.00) EPS for the quarter, beating analysts' consensus estimates of ($5.00) by $1.00.

When did GlycoMimetics' stock split?

GlycoMimetics shares reverse split on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 5th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of GlycoMimetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Bristol Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 8/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLYC
• CIK: 1253689
• Web: www.glycomimetics.com
• Phone: (240) 243-1201
• Fax: 301-738-2137
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.88 million
• Net Margins: N/A
• Pretax Margin: -397,340.00%
• Return on Equity: -230.74%
• Return on Assets: -177.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.92
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 64,532,000
• Free Float: 58,901,000
• Market Cap: $10.00 million
• Optionable: Optionable
• Beta: 1.62